Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Patients with resectable melanoma may benefit from adjuvant immunotherapy with pembrolizumab to help prevent recurrence after surgery. Mechanistic studies and animal models suggest that the addition of neoadjuvant treatment may enhance this benefit, by stimulating earlier proliferation of anti-tumor T cells in the tumor microenvironment.